Literature DB >> 15815704

Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation.

J Chen1, A J Zajac, S A McPherson, H-C Hsu, P Yang, Q Wu, X Xu, X Wang, K Fujihashi, D T Curiel, J D Mountz.   

Abstract

The virus-specific cytotoxic T lymphocyte (CTL) response is a major obstacle to effective delivery of adenovirus gene therapy. However, its relative role in viral clearance, transgene elimination and hepatotoxicity remains unclear. In this paper, we present an analysis of viral clearance and liver toxicity in relation to the induction of the virus-specific CD8 T-cell response revealed by an MHC class I tetramer. A surprisingly high number of tetramer+ CD8 T cells were found in the liver and lung and reached peak values at days 8 and 10, respectively, post-infection. Nearly 100% of these tetramer+ CD8 T cells expressed high levels of granzyme B and IFNgamma. Remarkably, liver viral load and liver enzyme elevation peaked early, at days 2 and 4, respectively, post-infection, before the specific CTL response was detectable. After generation of CTLs, there was only minimal liver damage or further decrease in virus titer. These results indicated that the primary peak response of tetramer+ CTLs does not correlate with the elimination of adenovirus or liver cytotoxic response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815704     DOI: 10.1038/sj.gt.3302494

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis.

Authors:  Bryan M Burt; George Plitas; Jennifer A Stableford; Hoang M Nguyen; Zubin M Bamboat; Venu G Pillarisetty; Ronald P DeMatteo
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

2.  Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Julia Davydova; Selwyn M Vickers; Masato Yamamoto
Journal:  Int J Cancer       Date:  2012-12-21       Impact factor: 7.396

3.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

4.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.

Authors:  Dan Wang; Haiwei Mou; Shaoyong Li; Yingxiang Li; Soren Hough; Karen Tran; Jia Li; Hao Yin; Daniel G Anderson; Erik J Sontheimer; Zhiping Weng; Guangping Gao; Wen Xue
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

5.  Maintenance of naïve CD8 T cells in nonagenarians by leptin, IGFBP3 and T3.

Authors:  Jian Chen; Jun Li; Fei Chu Lim; Qi Wu; Daniel C Douek; Donald K Scott; Eric Ravussin; Hui-Chen Hsu; S Michal Jazwinski; John D Mountz
Journal:  Mech Ageing Dev       Date:  2009-11-24       Impact factor: 5.432

6.  Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession.

Authors:  Jian Chen; John Wang; Jun Li; Qi Wu; Fei Chu Lim; Pingar Yang; Hui-Chen Hsu; David T Curiel; John D Mountz
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

7.  IL-33 induces nuocytes and modulates liver injury in viral hepatitis.

Authors:  Yuejin Liang; Zuliang Jie; Lifei Hou; Renan Aguilar-Valenzuela; David Vu; Lynn Soong; Jiaren Sun
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

8.  Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice.

Authors:  Yonas Getachew; Laura James; William M Lee; Dwain L Thiele; Bonnie C Miller
Journal:  Biochem Pharmacol       Date:  2009-12-29       Impact factor: 5.858

9.  A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy.

Authors:  Faizule Hassan; Sarah L Lossie; Ellen P Kasik; Audrey M Channon; Shuisong Ni; Michael A Kennedy
Journal:  PLoS One       Date:  2018-02-20       Impact factor: 3.240

Review 10.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.